Spontaneous Bacterial Peritonitis: Diagnosis and Management

Spontaneous Bacterial Peritonitis: Diagnosis and Management

Paracentesis criteria, empiric ceftriaxone, albumin infusion, and lifelong secondary prophylaxis in cirrhotic ascites

HepatologyGastroenterologyCirrhosis ComplicationsInfectious Disease

Executive Summary

Spontaneous bacterial peritonitis (SBP) is the infection of preexisting ascitic fluid in cirrhotic patients without an intra-abdominal source. SBP develops via bacterial translocation from gut lumen through impaired intestinal barrier, with secondary seeding of ascitic fluid in the setting of impaired ascitic fluid antimicrobial defenses (low complement, low protein, impaired opsonization). SBP affects 10-30% of hospitalized cirrhotic patients with ascites; in-hospital mortality remains 20-40% despite advances. Diagnosis requires diagnostic paracentesis with ascitic fluid PMN count ≥250 cells/μL (gold standard), which establishes diagnosis even before culture results. Cultures are positive in only 40-60% (low bacterial load) but should always be obtained in blood culture bottles inoculated at bedside. Pathogens are predominantly gram-negative enteric organisms (E. coli most common, Klebsiella, Enterobacter), with increasing gram-positive (Streptococcus, Enterococcus) and ESBL/MDR organisms in nosocomial cases. Empiric treatment is third-generation cephalosporin: ceftriaxone 2 g IV daily x 5 days or cefotaxime 2 g IV q8h x 5 days; broader spectrum (piperacillin-tazobactam 4.5 g IV q8h or meropenem 1 g IV q8h) for nosocomial, healthcare-associated, or recent quinolone prophylaxis cases. IV albumin 1.5 g/kg day 1 + 1 g/kg day 3 reduces hepatorenal syndrome risk and 90-day mortality, especially in patients with creatinine >1, BUN >30, or bilirubin >4 mg/dL. After SBP recovery, lifelong secondary prophylaxis with norfloxacin 400 mg PO daily (or alternatives) reduces recurrence from 70% to <20%. Primary prophylaxis is indicated for high-risk patients with low ascitic protein (<1.5 g/dL) plus advanced liver failure or impaired renal function. SBP marks a sentinel event in cirrhosis prognosis: 1-year survival is 30-50%; liver transplantation evaluation should be initiated promptly.
20-40%In-hospital mortality
≥250PMN/μL diagnostic threshold
70%1-year recurrence without prophylaxis
1.5 g/kgAlbumin day 1 dose

S1. Pathophysiology and Epidemiology

Mechanism of Bacterial Translocation

SBP develops through a multi-step pathway in cirrhotic patients with portal hypertension and ascites:

  1. Small intestinal bacterial overgrowth (SIBO): Cirrhosis is associated with reduced gut motility, hypochlorhydria, and impaired bile acid secretion, leading to overgrowth of enteric bacteria.
  2. Intestinal barrier disruption: Portal hypertension causes intestinal venous congestion, edema, and increased permeability ("leaky gut"). Bacterial endotoxin and viable bacteria cross the intact mucosal barrier.
  3. Bacterial translocation to mesenteric lymph nodes: Bacteria reach mesenteric lymph nodes via lymphatic transport. In healthy persons, immune containment occurs here; in cirrhosis, impaired phagocytic function permits passage.
  4. Bacteremia and ascitic fluid seeding: Translocated bacteria reach systemic circulation via thoracic duct, then seed ascitic fluid through transudation across the visceral peritoneum.
  5. Failed local defense: Ascitic fluid in cirrhosis has reduced complement, low protein (<1 g/dL impairs opsonization), and impaired neutrophil function, allowing infection to establish.

Risk Factors for SBP Development

CategoryRisk Factors
Severity of liver diseaseChild-Pugh C, MELD ≥18, total bilirubin >3 mg/dL, prothrombin time prolonged
Ascitic fluid characteristicsTotal protein <1 g/dL (key risk factor; impaired opsonization); SAAG >1.1 g/dL (portal hypertensive ascites)
Prior SBP episode70% recurrence within 1 year without prophylaxis
Variceal hemorrhageUp to 50% develop infection within 7 days; antibiotic prophylaxis (ceftriaxone or norfloxacin) is standard
Renal dysfunctionAKI, hepatorenal syndrome, hyponatremia (<130 mEq/L)
Proton pump inhibitor useIncreased SBP risk via gastric pH alteration and bacterial overgrowth (controversial; reduce or discontinue PPI in stable cirrhotic patients without firm indication)
Endoscopic proceduresIncreased risk after sclerotherapy, banding, ERCP

Pathogen Distribution

SettingCommon PathogensResistance Concerns
Community-acquired SBPE. coli (40-60%), Klebsiella (10-15%), Enterococcus (5-10%), Streptococcus (5-10%), other gram-negativesGenerally susceptible to ceftriaxone
Healthcare-associated SBPE. coli, Klebsiella with possible ESBL, Enterococcus, MSSA/MRSA, Pseudomonas (less common)Variable resistance; broaden empiric coverage based on local antibiogram
Nosocomial SBP (>48h hospitalization)ESBL Enterobacterales, Pseudomonas, Acinetobacter, MRSA, VRE, CandidaHigh MDR risk; carbapenem ± vancomycin; consider antifungal if Candida
Post-quinolone prophylaxisQuinolone-resistant E. coli, gram-positive cocci (Streptococcus, Enterococcus)Avoid quinolones empirically; broader gram-positive coverage often needed

Epidemiology

SBP affects 10-30% of cirrhotic patients hospitalized with ascites, with annual incidence of 8-30% in outpatient cirrhotics with ascites. The disease has remained a major cause of cirrhotic mortality despite advances in antibiotic therapy. Outcomes have improved with earlier diagnosis (universal paracentesis in admitted ascites), prompt antibiotic administration, and routine albumin administration. However, in-hospital mortality remains 20-40%; 1-year mortality after first SBP episode is 50-70%; this reflects underlying cirrhosis severity rather than treatment failure.

SBP Bacterial Translocation Pathway Schematic showing bacterial translocation from gut to ascitic fluid in cirrhosis SBP Pathophysiology: Bacterial Translocation Cirrhosis Portal hypertension Reduced motility SIBO Enteric overgrowth Gut leakage Mesenteric LN Translocation Failed containment Bacteremia Via thoracic duct Systemic spread Ascitic Fluid Infection (SBP) Low complement, low protein Failed opsonization PMN ≥250/μL diagnostic Treatment: Ceftriaxone 2g IV daily x 5d + Albumin 1.5 g/kg day 1, 1 g/kg day 3
Figure 1. SBP pathophysiology cascade from cirrhosis through gut bacterial translocation to ascitic fluid infection, with treatment principles.

S2. Clinical Presentation and Diagnostic Paracentesis

Symptoms and Signs

SBP presentation is often subtle in cirrhotic patients; classic peritoneal signs may be absent due to ascites distension and altered immune response. Maintain high suspicion in any decompensating cirrhotic with ascites:

PresentationFrequency
Fever (often low-grade)50-70%
Abdominal pain (often diffuse, mild)40-70%
Encephalopathy (new or worsening)30-50%
Worsening ascites or new diuretic resistance30-50%
Hypotension or sepsis presentation10-20%
Acute kidney injury30% develop during SBP course
Asymptomatic (detected on routine paracentesis)10-30%

Indications for Diagnostic Paracentesis

Diagnostic paracentesis is mandatory in all cirrhotic patients admitted to hospital with ascites, regardless of symptoms. Additional indications:

  • Any sign of infection: fever, leukocytosis, abdominal pain, encephalopathy
  • New onset acute kidney injury or hepatorenal syndrome
  • Variceal hemorrhage or any GI bleeding
  • New onset or worsening hepatic encephalopathy
  • Diuretic-resistant ascites or refractory ascites
  • Pre-procedure (large-volume paracentesis, TIPS placement)

Paracentesis Technique

StepDetail
Site selectionLeft lower quadrant preferred (safer than right; lateral to rectus muscle, 2 finger-breadths cephalad and medial to anterior superior iliac spine); use ultrasound guidance to confirm fluid pocket and avoid bowel/vessels
Coagulopathy considerationsRoutine FFP/platelet correction NOT indicated for diagnostic paracentesis even with INR up to 8 or platelets as low as 19,000; bleeding rate <1% in cirrhotic patients; only correct if active bleeding develops
Sterile techniqueChlorhexidine prep, sterile drape, sterile gloves; use Z-track technique to prevent fluid leakage
Local anesthesia1-2% lidocaine to skin, subcutaneous tissue, and peritoneum (anticipate "give" as needle enters peritoneum)
Diagnostic samplingAspirate 30-50 mL ascitic fluid for analysis; large-volume paracentesis (>5 L) reserved for therapeutic indication
Bedside culture inoculation10 mL ascitic fluid into each of 2 blood culture bottles (aerobic + anaerobic) at the bedside immediately - increases yield from 40% (lab-only) to 70-80%

Ascitic Fluid Analysis (Diagnostic Tests)

TestNormal in Cirrhotic AscitesSBP Findings
PMN count (cells/μL)<250≥250 = diagnostic (gold standard regardless of culture); subtract 1 PMN per 250 RBCs if blood-tinged
Total WBCVariableOften elevated; less specific than PMN count
Culture (bedside-inoculated)NegativePositive in 40-60% of SBP; usually monomicrobial; gram-negative enterics common
Albumin (calculate SAAG = serum albumin - ascitic albumin)SAAG >1.1 g/dL (portal HTN)Unchanged by infection; useful for differential
Total protein<1 g/dL (low) or higherLow protein (<1 g/dL) is risk factor for SBP, NOT a diagnostic finding
Glucose>50 mg/dL (similar to serum)Glucose <50 mg/dL suggests SECONDARY peritonitis (perforation, abscess)
LDH<225 IU/L (similar to serum upper limit)LDH >225 IU/L (above serum normal) suggests secondary peritonitis
Gram stainNegativePositive gram stain suggests secondary peritonitis (high bacterial load); SBP gram stain usually negative due to low colony count
Cytology (if malignancy suspected)NegativeNot part of SBP workup

SBP Diagnostic Criteria Summary

Diagnostic Threshold

SBP is diagnosed when ascitic fluid PMN count is ≥250 cells/μL in the absence of an intra-abdominal source of infection. Treatment is initiated immediately based on PMN count alone, without waiting for culture results. Culture-negative neutrocytic ascites (CNNA: PMN ≥250 with negative culture) is treated identically to culture-positive SBP.

Clinical Pearl - Bedside Inoculation Doubles Yield

The single most important technical step in SBP diagnosis is inoculating ascitic fluid directly into blood culture bottles AT THE BEDSIDE, not sending fluid in a tube to the lab. Bedside inoculation increases culture yield from 40% (lab-processed fluid) to 70-80% (bedside-inoculated). Use 10 mL into each aerobic and anaerobic blood culture bottle, immediately after fluid is withdrawn. This identifies the pathogen for targeted therapy and helps detect ESBL/MDR organisms requiring escalated coverage.

Common Pitfall - Skipping Paracentesis Due to Coagulopathy

A frequent error is delaying or avoiding paracentesis in cirrhotic patients with elevated INR, low platelets, or low fibrinogen. Routine correction with FFP, platelets, or cryoprecipitate is NOT indicated for diagnostic paracentesis; bleeding complications occur in <1% even with INR >5 or platelets <50,000. The risk of missed SBP (mortality 20-40%) far exceeds the rare bleeding risk. Use ultrasound guidance, lateral approach, Z-track technique, and avoid sites with visible vessels - then proceed regardless of coagulation parameters.

S3. Variants and Differential Diagnosis

SBP Variants

VariantPMN CountCultureTreatment
Classic SBP≥250/μLPositive (monomicrobial)Treat as SBP; tailor antibiotic to organism
Culture-Negative Neutrocytic Ascites (CNNA)≥250/μLNegativeTreat as SBP (identical empiric regimen); represents true SBP with culture failure
Monomicrobial Non-Neutrocytic Bacterascites (MNB)<250/μLPositive (monomicrobial)Repeat paracentesis: if symptomatic OR PMN now ≥250 OR same organism, treat as SBP; if asymptomatic and culture clears spontaneously, observe
Polymicrobial Bacterascites<250/μLMultiple organismsSuspect bowel perforation from paracentesis needle; observe with serial paracentesis; rarely requires intervention

Differential: Secondary Bacterial Peritonitis

Secondary peritonitis (perforation, abscess, gangrenous cholecystitis) requires surgical evaluation, not just antibiotics. Distinguishing from SBP is critical because mortality from missed surgical pathology approaches 100%.

FeatureSBPSecondary Peritonitis
PMN count≥250/μLOften >1000/μL
CultureMonomicrobial (40-60%)Polymicrobial (mixed enteric flora)
Total proteinVariable; often low (<1 g/dL)Often >1 g/dL
Glucose>50 mg/dL (close to serum)<50 mg/dL (consumed by bacteria)
LDH>serum upper limit
Gram stainUsually negativeOften positive with multiple morphologies
CEA, alkaline phosphataseNormalCEA >5 ng/mL OR alkaline phosphatase >240 IU/L (Runyon's criteria)
Clinical courseImproves with antibiotics 48hNo improvement; worsening despite antibiotics
ImagingNormal (ascites only)Free air, abscess, perforation, complicated obstruction

Runyon's criteria for secondary peritonitis (≥2 of 3 = high suspicion):

  1. Total protein >1 g/dL
  2. Glucose <50 mg/dL
  3. LDH > upper limit of normal serum

Plus: CEA >5 ng/mL OR alkaline phosphatase >240 IU/L (highly specific for perforation). When secondary peritonitis is suspected: emergent abdominal CT with contrast, surgical consultation, broaden antibiotics (carbapenem + metronidazole + consider vancomycin), and source control intervention.

Other Differentials

ConditionDistinguishing Features
Tuberculous peritonitisLymphocyte-predominant ascites (>40%); ADA >36-40 U/L; high SAAG <1.1 (exudative); PCR or culture for M. tuberculosis; chronic course; weight loss
Malignant ascitesSAAG <1.1 (exudate); high total protein >2.5 g/dL; cytology positive; CEA elevated; ascitic LDH high; cancer history
Pancreatic ascitesAscitic amylase >1000 U/L; history of pancreatitis or pancreatic surgery; chronic pancreatitis with ductal disruption
Chylous ascitesMilky appearance; triglycerides >200 mg/dL; lymphatic obstruction (malignancy, surgery, lymphoma)
Cardiac ascitesSAAG ≥1.1 (transudate); high total protein >2.5 g/dL (CHF); echocardiogram shows reduced EF or restrictive physiology
Nephrogenic ascitesEnd-stage renal disease on dialysis; rare; transudate

S4. Empiric Antibiotic Therapy and Albumin

Empiric Antibiotic Selection

SettingFirst-Line RegimenDuration
Community-acquired SBP, no recent hospitalization, no quinolone prophylaxisCeftriaxone 2 g IV daily OR Cefotaxime 2 g IV q8h5 days (extended to 7-10 days if culture-proven gram-negative bacteremia or slow improvement)
Healthcare-associated SBP (hospitalized within 90 days, healthcare contact)Piperacillin-tazobactam 4.5 g IV q8h OR Cefepime 2 g IV q8h + consider adding metronidazole if anaerobic risk5-7 days
Nosocomial SBP (developed >48h after admission)Meropenem 1 g IV q8h + Vancomycin 25-30 mg/kg IV loading, then AUC-guided5-10 days; tailor to culture; consider antifungal if Candida
SBP on quinolone prophylaxisAvoid quinolones empirically; use third-generation cephalosporin OR pip-tazo + add gram-positive coverage5-7 days
Severe sepsis or septic shockMeropenem 1 g IV q8h + Vancomycin 25-30 mg/kg IV loading ± antifungal; ICU admission7-14 days; tailor to culture and clinical response
ESBL/CRE risk (prior colonization, MDR exposure)Meropenem 1 g IV q8h for ESBL; Ceftazidime-avibactam 2.5 g IV q8h for CRE7-14 days; antimicrobial stewardship consultation
True beta-lactam allergyVancomycin + Aztreonam 2 g IV q8h; OR Vancomycin + Ciprofloxacin 400 mg IV q12h if no quinolone resistance5-7 days; consider desensitization for severe infection

Antibiotic De-escalation

Once cultures return, narrow antibiotics to the most appropriate agent:

  • Susceptible E. coli or Klebsiella → ceftriaxone 2 g IV daily for 5 days total
  • ESBL E. coli or Klebsiella → ertapenem 1 g IV daily or meropenem 1 g IV q8h for 7-10 days
  • Pseudomonas → cefepime 2 g IV q8h or pip-tazo 4.5 g IV q8h for 7-14 days
  • Enterococcus faecalis → ampicillin 2 g IV q4h for 7-10 days
  • Enterococcus faecium (often vancomycin-resistant) → daptomycin 8-10 mg/kg IV daily or linezolid 600 mg IV/PO q12h
  • MRSA → vancomycin (AUC 400-600 mg·h/L) or daptomycin 8-10 mg/kg IV daily for 14 days
  • Candida → fluconazole 800 mg IV loading, then 400 mg IV daily if susceptible; echinocandin if azole-resistant or critically ill

Albumin Infusion - Reduces HRS and Mortality

The landmark Sort et al. trial (NEJM 1999) showed that IV albumin reduced hepatorenal syndrome from 33% to 10% and 90-day mortality from 41% to 22% in SBP patients. Mechanisms include increased plasma oncotic pressure, splanchnic vasoconstriction, improved renal perfusion, and binding of inflammatory cytokines.

Albumin IndicationRecommended Dose
Standard SBP (especially Cr >1, BUN >30, or bilirubin >4 mg/dL)Day 1: Albumin 25% 1.5 g/kg IV (max 100 g) within 6 hours of diagnosis
Day 3: Albumin 25% 1.0 g/kg IV (max 50 g)
All SBP patients (some guidelines including AASLD)Same regimen regardless of renal/liver dysfunction; benefit demonstrated even in lower-risk subgroups
Hepatorenal syndrome AKI developmentAlbumin 1 g/kg/day day 1, then 25-50 g IV daily + vasoconstrictor (terlipressin, norepinephrine, or octreotide+midodrine)
Large-volume paracentesis (LVP) >5LAlbumin 6-8 g per liter ascitic fluid removed (separate indication, not for infection prevention)

Reassessment at 48 Hours

Repeat paracentesis at 48 hours to assess treatment response:

  • PMN count decreased by ≥25% from baseline → continue same antibiotic; expect clinical improvement
  • PMN count not decreased ≥25% → consider treatment failure; broaden antibiotic coverage; reassess for secondary peritonitis (CT abdomen, surgical consultation); culture follow-up
  • New positive culture for organism not covered → switch antibiotics
  • Clinical deterioration → broaden coverage immediately, ICU evaluation, source control investigation

Avoid Aminoglycosides in SBP

Aminoglycosides (gentamicin, tobramycin, amikacin) should be avoided in cirrhotic SBP patients due to high nephrotoxicity risk in the setting of hepatorenal physiology. Aminoglycoside-induced AKI in cirrhotic patients can precipitate hepatorenal syndrome and rapidly fatal decline. Third-generation cephalosporins, piperacillin-tazobactam, and carbapenems achieve adequate coverage without renal toxicity. If aminoglycoside is unavoidable (severe MDR pseudomonas), use single daily dosing with strict therapeutic monitoring and restrict to shortest possible duration.

S5. Hepatorenal Syndrome and Complications

Hepatorenal Syndrome - AKI (HRS-AKI)

HRS-AKI (formerly type 1 HRS) is a functional renal failure in cirrhosis characterized by intense renal vasoconstriction in response to splanchnic vasodilation and effective arterial underfilling. SBP precipitates HRS in up to 30% of cases despite albumin therapy. Without effective treatment, HRS-AKI carries 80-90% short-term mortality.

Criterion (ICA-AKI 2015 Revised)Detail
Diagnosis of cirrhosis with ascitesRequired
AKI by ICA criteriaSCr increase ≥0.3 mg/dL within 48h, or ≥50% from baseline within 7 days
No improvement after 48h volume expansionAlbumin 1 g/kg IV daily (max 100 g/day) x 2 days + diuretic withdrawal
Absence of shockRequired (excludes prerenal azotemia from septic shock)
No nephrotoxic drugsDiscontinue NSAIDs, aminoglycosides, IV contrast
No structural kidney diseaseProteinuria <500 mg/day, no hematuria, normal renal ultrasound

HRS-AKI Treatment

TherapyDosingNotes
Terlipressin (FDA approved 2022)1 mg IV q4-6h; titrate to 2 mg q4h if SCr does not decrease ≥25% in 3 days; max 12 mg/dayFirst-line per AASLD; reduces SCr in 30-50%; avoid if hypoxia (CONFIRM trial showed respiratory failure risk in advanced lung disease)
Albumin (concurrent with vasoconstrictor)1 g/kg day 1 (max 100g), then 25-50 g/day IVContinue throughout vasoconstrictor course; do not exceed CVP-guided fluid status
Norepinephrine (alternative to terlipressin)0.5-3 mg/hr IV titrated to MAP increase 10 mmHgICU setting required; acceptable alternative; equivalent efficacy in some studies
Octreotide + Midodrine + Albumin (where terlipressin unavailable)Octreotide 100-200 mcg SC q8h + Midodrine 7.5-12.5 mg PO q8h + AlbuminLess effective than terlipressin; reasonable bridge in non-ICU settings
Renal replacement therapyCRRT or intermittent HD as neededBridge to transplant; not definitive therapy
Liver transplantationListing prioritized for HRSOnly definitive therapy; HRS reversal does not eliminate transplant need; combined liver-kidney transplant if HRS sustained >4-8 weeks despite therapy

Other SBP Complications

ComplicationFrequencyManagement
Hepatic encephalopathy30-50%Lactulose 20-30 g PO/PR q1-2h to BMs, then 15-30 g PO q6-8h; rifaximin 550 mg PO BID for refractory; treat precipitant (SBP itself)
Variceal hemorrhage10-20%Octreotide 50 mcg IV bolus, then 50 mcg/hr infusion x 5 days; emergent endoscopy with band ligation; consider TIPS for refractory bleeding
Septic shock5-15%Aggressive fluid resuscitation (crystalloid + albumin), norepinephrine first-line, vasopressin add-on, broad-spectrum antibiotics, ICU admission; mortality >50%
Pleural effusion (hepatic hydrothorax)VariableDiuretics; thoracentesis if symptomatic; avoid chest tube (risk of fluid loss, infection); TIPS for refractory cases
Adrenal insufficiency30-50% in critically ill cirrhoticsHydrocortisone 200 mg/day IV (50 mg q6h or continuous infusion) in septic shock with vasopressor requirement
Acute-on-chronic liver failure (ACLF)Common precipitantSupportive care; transplant evaluation urgent if ACLF grade 2-3; mortality 30-90% depending on grade

SBP as Sentinel Event for Transplant Evaluation

First episode of SBP carries 1-year mortality of 50-70%, regardless of treatment success of the acute infection. SBP marks a transition to advanced cirrhosis with substantially worse prognosis. All patients surviving SBP should undergo expedited liver transplantation evaluation if not already listed: confirm MELD-Na score, evaluate for transplant contraindications (active alcohol/substance use, severe pulmonary HTN, uncontrolled HCC, severe cardiac/pulmonary disease), and place patient on transplant list as soon as eligibility confirmed. Time on the list and MELD score guide priority. SBP itself does not earn MELD exception points but signals advanced disease requiring urgent evaluation.

S6. Prophylaxis and Long-term Management

Secondary SBP Prophylaxis (After First Episode)

All patients who survive an SBP episode should receive lifelong secondary prophylaxis (or until liver transplantation). Without prophylaxis, recurrence rate is 70% within 1 year. With prophylaxis, recurrence falls to <20%.

AntibioticDoseNotes
Norfloxacin (preferred where available)400 mg PO dailyMost evidence; selective gut decontamination of gram-negatives; first-line per AASLD/EASL
Ciprofloxacin500 mg PO daily OR 750 mg PO weeklyAlternative; daily dosing more effective than weekly in trials
Trimethoprim-sulfamethoxazole1 DS tab (160/800 mg) PO dailyAlternative for quinolone-allergic or quinolone-resistant settings; monitor for hyperkalemia and renal function
Rifaximin550 mg PO BIDEmerging evidence; reduces SBP and HE recurrence in some studies; not yet first-line for SBP prophylaxis alone

Primary SBP Prophylaxis (Without Prior SBP)

Primary prophylaxis is indicated for high-risk patients who have NEVER had SBP but have:

  • Ascitic fluid total protein <1.5 g/dL AND
  • At least one of:
    • Renal dysfunction: SCr ≥1.2 mg/dL, BUN ≥25 mg/dL, or sodium ≤130 mEq/L
    • Advanced liver failure: Child-Pugh ≥9 points with bilirubin ≥3 mg/dL

Primary prophylaxis regimen: norfloxacin 400 mg PO daily (or alternative). Continue until ascites resolves, transplantation, or death.

Variceal Hemorrhage Prophylaxis

All cirrhotic patients with variceal or non-variceal upper GI bleeding require antibiotic prophylaxis from admission for 7 days, regardless of ascites or prior SBP. Bacterial infection complicates 50% of cirrhotic GI bleeds within 7 days.

Patient SettingAntibiotic
Decompensated cirrhosis (Child-Pugh B/C, advanced disease)Ceftriaxone 1 g IV daily x 7 days
Compensated cirrhosis (Child-Pugh A)Norfloxacin 400 mg PO BID x 7 days

Lifestyle and Medical Management

RecommendationDetail
Sodium restriction2 g (88 mEq) sodium per day; central to ascites management
Fluid restriction1-1.5 L/day if serum sodium <130 mEq/L
Alcohol abstinenceMandatory; consider naltrexone or acamprosate; avoid disulfiram in liver failure
Diuretic managementSpironolactone 100 mg PO daily, titrate to 400 mg + Furosemide 40 mg PO daily, titrate to 160 mg (100:40 ratio); hold diuretics during AKI
Beta-blockers (variceal prophylaxis)Carvedilol 6.25-12.5 mg PO BID or nadolol 40-80 mg PO daily; controversial in refractory ascites and SBP - hold if hypotensive (SBP <90), AKI, or active SBP per "window hypothesis"
PPI useReassess indication; discontinue if no firm indication (PPI use associated with SBP and C. difficile)
VaccinationsInfluenza annually; pneumococcal (PCV15 then PPSV23); hepatitis A and B; COVID-19; do not use live vaccines in advanced cirrhosis
HCC surveillanceUltrasound + AFP every 6 months in cirrhotic patients
Liver transplant evaluationInitiate at diagnosis of any SBP; MELD-Na monitoring

When to Refer for Hepatology and Liver Transplantation

Hepatology/transplant referral is appropriate for: (1) any first SBP episode; (2) recurrent SBP despite prophylaxis; (3) hepatorenal syndrome (HRS-AKI or HRS-NAKI); (4) refractory ascites requiring large-volume paracentesis >2 times monthly; (5) MELD-Na ≥15 (transplant evaluation threshold); (6) hepatic encephalopathy episodes requiring hospitalization; (7) variceal hemorrhage; (8) HCC diagnosis; (9) consideration of TIPS for refractory ascites or variceal bleeding. Outpatient follow-up: hepatology within 2 weeks of SBP discharge for prophylaxis verification, MELD calculation, and transplant evaluation initiation; gastroenterology for variceal surveillance per recommended interval (1-2 years if no varices, annually if small varices, at hemorrhage prophylaxis if medium-large).

Long-term Outcomes

OutcomeWithout TransplantWith Transplant
Survival 30 days post-SBP70-80%95%+ (if transplanted before next decompensation)
Survival 1 year post-SBP30-50%85-90%
Survival 5 years post-SBP15-25%70-80%
SBP recurrence (no prophylaxis)70% in 1 year—
SBP recurrence (with prophylaxis)15-25% in 1 year—
HRS development after SBP30% (10% with albumin)—

Clinical Pearl - Beta-Blocker Window Hypothesis

The traditional teaching that all cirrhotics on non-selective beta-blockers (carvedilol, nadolol, propranolol) for variceal prophylaxis should remain on them indefinitely has been challenged. The "window hypothesis" suggests beta-blockers benefit compensated cirrhotics but may worsen outcomes in advanced disease (refractory ascites, SBP, HRS, hypotension) by impairing cardiac output reserve. Current AASLD guidance: hold or discontinue beta-blockers if SBP <90 mmHg, AKI, hyponatremia <120, or active SBP. Reassess after recovery; restart cautiously at lower dose if hemodynamically tolerated.

Common Pitfall - Inadequate Albumin Dosing

A frequent error is omitting or underdosing albumin in SBP, particularly in patients without obvious renal dysfunction or jaundice. The Sort trial showed albumin reduces 90-day mortality from 41% to 22% across SBP patients; benefit is greatest in those with Cr >1, BUN >30, or bilirubin >4, but mortality benefit extends to lower-risk groups. Use the full dose: 1.5 g/kg on day 1 within 6 hours of diagnosis (not over multiple days), and 1 g/kg on day 3. Common errors include using 5% albumin (use 25%), splitting the day 1 dose over 24 hours (give as bolus or short infusion), or omitting day 3 dose.

S7. Practice Insights: Bedside Notes on SBP

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Death in spontaneous bacterial peritonitis usually arrives through renal failure rather than through the infection itself — SBP's mortality is set by three things: time-to-paracentesis at admission, day-1 albumin infusion, and recognizing secondary bacterial peritonitis early enough to operate. In experienced hands the pivot points are paracentesis on EVERY cirrhotic admission with ascites (not just those with abdominal symptoms), albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 (no negotiation), and Runyon criteria assessment to distinguish primary SBP from secondary that needs surgery. Seasoned clinicians track three things during management: PMN trajectory (repeat para if clinical doubt at 48h), creatinine (HRS prevention is the goal), and cefotaxime susceptibility from culture.

What the Guideline Misses — Paracentesis on EVERY Cirrhotic Admission

Diagnostic paracentesis is mandated at admission by guidelines but in experienced practice this is the most commonly skipped intervention. Atypical presentations (no fever, no abdominal pain — just confusion or AKI in cirrhotic) hide SBP. About 1 in 6 of the SBP cases had no classic symptoms; the diagnosis came from routine admission paracentesis. clinicians order paracentesis as part of the admission order set for any cirrhotic patient with ascites.

Patterns That Repeat in Practice — Albumin Day 1 + Day 3 Saves Kidneys

Sort et al 1999 trial showed albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 cuts HRS by ~60% and mortality meaningfully. In practice this is hard-wired into the SBP order set — neither dose negotiable. The day-3 dose is the one most frequently forgotten by floor teams. Experienced practitioners round on this every day-3 morning to make sure it goes in.

Secondary Peritonitis Detection

Secondary bacterial peritonitis (perforated viscus, abscess) has high mortality if treated as SBP. Runyon criteria for SBP: ascitic fluid glucose <50 mg/dL + protein >1 g/dL + LDH > ULN serum (2 of 3 = secondary likely). Polymicrobial culture or anaerobes or fungi also suggest secondary. CT abdomen and surgical consultation are mandatory. About 1 in 20 of the "SBP" workups turn out to be secondary — surgery saves lives.

Bedside Heuristic — Repeat Paracentesis at 48 Hours

If clinical improvement is ambiguous or the patient remains febrile/encephalopathic at 48 hours, clinicians repeat paracentesis. PMN drop ≥25% from baseline confirms response; failure to drop triggers broader-spectrum coverage and CT imaging for secondary peritonitis. About 1 in 8 of the SBP cases require regimen change based on 48h paracentesis; without it clinicians would have continued ineffective therapy.

A Case That Reframed The Approach — Secondary Peritonitis Almost Missed

A man in his late 50s with Child C cirrhosis admitted with fever, encephalopathy, and ascites. Admission paracentesis: PMN 850, culture growing Klebsiella + E. coli + Bacteroides (polymicrobial). Started cefotaxime + albumin. By hour 48 he was deteriorating: fever persistent, lactate rising, new RLQ tenderness. Repeat paracentesis: PMN 1800 (worse); fluid analysis ascitic glucose 35, protein 2.4, LDH 380 (serum ULN 250). All three Runyon criteria met → secondary peritonitis suspected. CT abdomen showed perforated diverticulum with abscess. Surgery, drainage, expanded antibiotics (pip-tazo + metro). He survived but required prolonged ICU stay. What clinicians learned: polymicrobial growth + Runyon criteria positivity is a surgical emergency. The treating clinicians now check Runyon criteria on every SBP fluid analysis, not just "concerning" cases.

Bedside lesson: every ascitic fluid analysis gets glucose + protein + LDH + cell differential. Runyon ≥2 of 3 criteria + polymicrobial growth = secondary peritonitis until proven otherwise. CT and surgical consult same hour.

Practice Pattern Refinements That Diverge From Standard Guidelines

  1. Diagnostic paracentesis on EVERY cirrhotic admission with ascites — built into admission order set. Don't wait for "fever or abdominal pain." About 1 in 6 SBP cases present atypically. The paracentesis is low-risk; missing SBP is high-mortality.
  2. Albumin 1.5 g/kg day 1 + 1.0 g/kg day 3 — hard-wired in order set with day-3 reminder. Both doses non-negotiable. The day-3 dose gets forgotten most often. Experienced clinicians literally round on day 3 to verify it gets administered.
  3. Full Runyon criteria on every ascitic fluid (glucose + protein + LDH) — not just cell count. Standard ordering is cell count + culture. clinicians add glucose, protein, LDH on every fluid to screen for secondary peritonitis. The cost is trivial; the diagnostic miss is fatal.
  4. Repeat paracentesis at 48h if clinical doubt — confirm ≥25% PMN drop. Clinical assessment alone misses non-responders. The 48h repeat para catches both treatment failure (resistant organism, secondary peritonitis) and overcautious teams who would have escalated unnecessarily.
SBP Algorithm — Universal Paracentesis, Albumin Day 1+3, Runyon for Secondary Cirrhotic admission → paracentesis → PMN ≥250 → cefotaxime + albumin → Runyon criteria check → 48h repeat SBP Algorithm — Paracentesis on Every Admission, Albumin D1+D3, Runyon Always Cirrhotic admission + ascites Order set: paracentesis MANDATORY Diagnostic paracentesis: PMN + culture + glucose + protein + LDH ~1 in 6 SBP presents WITHOUT fever or abdominal pain PMN ≥250 cells/mm³ Diagnostic alone (culture-negative SBP common) Antibiotic + Albumin Cefotaxime 2g IV q8h × 5d Albumin 1.5 g/kg D1 + 1.0 g/kg D3 Carbapenem if healthcare-acquired Both albumin doses required ⚠️ Runyon criteria check Glucose <50 + Protein >1 + LDH > serum ULN 2 of 3 = secondary peritonitis + polymicrobial = secondary likely CT + surgical consult NOW 48-hour repeat paracentesis if clinical doubt — confirm ≥25% PMN drop Failure → broader spectrum + CT for secondary peritonitis Observed: paracentesis on every cirrhotic admission catches ~1 in 6 atypical SBP. Albumin D1+D3 cuts HRS ~60%. — gomdori, MD
RELATED TOOL
Ascites SAAG & SBP Diagnostic Assistant — enter an ascitic fluid panel and see what AASLD and EASL make of it — SAAG against the 1.1 g/dL threshold and the SBP criteria.

Frequently Asked Questions

How is spontaneous bacterial peritonitis diagnosed?
SBP diagnosis requires diagnostic paracentesis showing ascitic fluid PMN count greater than or equal to 250 cells per microliter, in the absence of an intra-abdominal source of infection. Ascitic fluid culture is positive in only 40-60% of cases (low colony count infection) and is not required for diagnosis. Variants include culture-negative neutrocytic ascites (PMN >=250 with negative culture - treat as SBP) and monomicrobial non-neutrocytic bacterascites (positive culture with PMN <250 - treat only if symptomatic or high-risk).
What is the recommended empiric antibiotic for SBP?
Third-generation cephalosporins are the empiric standard: ceftriaxone 2g IV daily or cefotaxime 2g IV q8h for 5 days. For nosocomial SBP, recent quinolone prophylaxis, or healthcare-associated infections, broader-spectrum coverage is needed: piperacillin-tazobactam 4.5g IV q8h or meropenem 1g IV q8h to cover ESBL Enterobacterales, Pseudomonas, and gram-positives. Adjust based on local resistance patterns and culture results.
When is albumin indicated in SBP?
IV albumin reduces hepatorenal syndrome risk and 90-day mortality in SBP. The standard regimen is albumin 1.5 g/kg IV on day 1 (within 6 hours of diagnosis) and 1 g/kg IV on day 3. Greatest benefit is seen in patients with creatinine greater than 1 mg/dL, BUN greater than 30 mg/dL, or total bilirubin greater than 4 mg/dL. Some guidelines recommend albumin for all SBP patients regardless of these criteria; others restrict to those with high-risk features.
Who should receive SBP secondary prophylaxis?
All patients who survive an SBP episode should receive lifelong secondary prophylaxis with norfloxacin 400 mg PO daily, ciprofloxacin 500 mg PO daily, or trimethoprim-sulfamethoxazole 1 DS tablet daily. Without prophylaxis, recurrence rate is 70% within one year. Primary prophylaxis is indicated for patients with ascitic fluid total protein less than 1.5 g/dL plus impaired renal function (Cr greater than 1.2, BUN greater than 25, or sodium less than 130) or advanced liver failure (Child-Pugh greater than 9 with bilirubin greater than 3).
How is hepatorenal syndrome related to SBP managed?
Hepatorenal syndrome (HRS) develops in up to 30% of SBP patients despite albumin and is the leading cause of SBP-related mortality. HRS-AKI (formerly type 1) is treated with terlipressin 1 mg IV q4-6h titrated to 2 mg q4h plus albumin 1 g/kg day 1 then 25-50g daily, OR with norepinephrine plus albumin, OR with octreotide plus midodrine plus albumin where terlipressin is unavailable. Liver transplantation evaluation is essential. Reversal of HRS does not eliminate the need for transplant in most patients.
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *